drugset
drugset / Trial / NCT01304303

Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

NCT01304303 ↗

Phase 1 Completed 57 enrolled Sun Pharma Advanced Research Company Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase I study of SPARC1023 alone and in combination with carboplatin

Timeline

Start
2011-10
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SPARC1023 Unknown — Intravenous

Indications

high grade malignant neoplasm